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In 2012 there were 14.1 million new cancer cases 
worldwide [1]. The frequency of metastasis to the 
spine depends on the primary cancer, with the majority 
of metastasising cancers being breast, lung and pros­
tate cancers [2]. Between 5% and 10% of all cancer pa­
tients develop spinal metastases during the course of 
their disease [3]. This percentage is higher for patients 
with advanced disease [4].
Treatment options for patients with spinal meta­
stasis are usually palliative, focusing on improving the 
quality of the remaining life of the patients and their 
families by reducing or completely eliminating pain. 
Traditional pain­relieving therapies include analgesics, 
bed rest, steroids, radiotherapy and radiosurgery [5]. 
Analgesics and bed rest are often not an effective treat­
ment in cancer patients with painful vertebral frac tures 
due to spinal metastasis. Traditional open instru­
mented spinal surgery (i.e., the use of medical implants 
such as rods, screws, etc.) in general anaesthesia is con­
sidered to be optimal management. This is usually not 
an option in patients with advanced cancer and a poor 
general condition due to short life expectancy and a 
lengthy hospitalisation and recovery period. 
Vertebral augmentation, including vertebroplasty 
(PVP), has been reported as a minimally invasive treat­
ment option that can be performed on an outpatient 
basis. The procedure is considered to be well suited for 
treatment of malignant spine disease because of the 
proven rapid pain relief compared with the other treat­
ment options [6]. 
PVP stabilises the fractured vertebrae thereby pre­
venting microscopic movements and macroscopic col­
lapse. Furthermore, it has been suggested that bone ce­
ment (poly­methyl methacrylate (PMMA)) induces 
exothermic reactions that are toxic to the nerve endings 
[7].
Vertebral augmentation was developed in the late 
1980s in France for the treatment of vertebral haeman­
giomas and osteolytic vertebral tumours [8], but has 
since gained popularity for  treatment of osteoporotic 
fractures. Under imaging guidance, the needle is trad­
itionally inserted through the pedicles (Figure 1A) [9]. 
PMMA is injected into the vertebral body under imag­
ing guidance to minimise extravasation. PVP can be 
performed under local anaesthesia, which prevents 
prolonged immobilisation [9]. This is of pivotal import­
ance, considering comorbidities and the advanced dis­
ease progression of this study population. Additionally, 
it minimises length of hospitalisation, which may be of 
great value to the terminally ill patient.
The procedure also provides an opportunity to ob­
ABSTRACT
INTRODUCTION: In cancer patients with painful vertebral 
fractures due to spinal metastasis, traditional pain-relieving 
therapies include analgesics, bed rest, steroids, radio ther-
apy, etc. These treatment modalities are often ineffective. 
Traditional spinal surgery in general anaesthesia is usually 
not an option in patients with advanced cancer and in a 
poor general condition. Percutaneous vertebroplasty (PVP) 
has been reported as a minimally invasive treatment option 
with apparent rapid pain relief compared with other 
conventional treatment options. The objective of this study 
was to assess the safety and efficacy of PVP in patients 
with malignant spinal lesions. 
METHODS: From the National Danish Surgical Spine 
Database, DaneSpine, 30 consecutive cancer patients with 
vertebral fractures who underwent PVP from 2013 to 2017 
were identified. From DaneSpine, the European Quality of Life 
– 5 Dimensions Questionnaire (EQ-5D) and the Oswestry 
Disability Index (ODI) scores were collected pre- and post-
operatively. Data on the incidence of complications and 
poly-methyl methacrylate leaks were obtained by review of 
medical records and plain post-operative X-rays. 
RESULTS: The mean improvement in EQ-5D scores from 
baseline was 0.30 (p < 0.01) after three months, and 0.25  
(p = 0.01) after one year. The ODI improved from 44.1 to 23.3 
(p < 0.01). Despite a cement leakage rate of 14.8%, no 
patients presented with any clinically significant symptoms. 
CONCLUSIONS: PVP is a safe procedure providing a 
statistically significant and clinically relevant improvement 
in quality of life and function of patients with cancer-related 
vertebral compression fractures. Our findings may provide 
useful information to healthcare professionals who are 
treating cancer.
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TRIAL REGISTRATION: not relevant.
2DANISH MEDICAL JOURNAL
 Dan Med J 65/10  October 2018
tain a bone marrow biopsy prior to cement injection. 
Studies have shown underlying malignancy in 4.7­
4.9% of all patients [10, 11] with vertebral compres­
sion fractures initially thought to be due to osteopor­
osis.
The aim of this study was to determine the safety 
and efficacy of PVP for vertebral compression fractures 
caused by malignant spinal disease.
METHODS
This case series included 30 consecutive patients who 
had been treated with PVP at our institution from 1 
January 2013 to 1 March 2017. The patient demo­
graphics are presented in Table 1. Potential candidates 
for vertebroplasty at our facility with diagnosed malig­
nant vertebral lesions are primarily referred for evalu­
ation by haematologists, oncologists or general prac­
titioners. The procedure is performed under local 
anaesthesia, and the patients are usually discharged 
within the next few hours. Three months post­opera­
tively, the patient is seen for a clinical and radiologic 
examination of the spine. 
The inclusion criteria were: 1) patients treated with 
PVP for painful vertebral compression fractures at one 
or more levels; 2) patients with histologically and/or 
radiologically verified spinal malignancy. In patients 
with multiple myeloma, a diagnostic bone marrow bi­
opsy prior to the operation was accepted as an eligibil­
ity criterion; and 3) patients treated for more than one 
year prior to the collection of data to allow at least one 
year of follow­up. 
The medical records of all patients treated with PVP 
at our institution were screened retrospectively, and 
we obtained information on primary malignancy, histo­
logical examination, magnetic resonance imaging 
(MRI) evaluations including posterior wall defects and 
possible complication. Cement leakage was identified 
using the three­month post­operative X­ray. The re­
maining data presented in Table 1 and Table 2 were 
extracted from the national spine surgical PRO­data­
base (DaneSpine), which consists of prospectively col­
lected data. 
Outcomes were assessed pre­ and post­operatively. 
The primary efficacy outcome was quality of life meas­
ured by the European Quality of Life – 5 Dimensions 
Questionnaire (EQ­5D). Secondary outcomes included 
the Oswestry Disability Index (ODI) questionnaire, 
pain, relation between posterior wall defect and com­
plications, and rate of cement leakage. Posterior wall 
defects were not reported consistently in the MRI de­
scriptions. In the case of a lacking description, two au­
thors re­evaluated the MRI and consulted a radiologist 
if in doubt.
Data on the EQ­5D and the ODI are expressed as 
mean ± standard deviation. Paired t­tests were used to 
compare these parameters before and after PVP.
Section 1 of the ODI questionnaire was used to as­
sess pain prior to surgery and at the one­year follow­
up, since the visual analogue scale (VAS) was not re­
ported consistently. This item categorises pain into one 
of six statements ranging in severity from “0) I have no 
pain at the moment” to “5) The pain is the worst imagi­
nable at the moment”. Pain is presented as categorical 
data in the ODI questionnaire, and a chi­squared test 
was performed to evaluate the difference between 
baseline and follow­up. 
A threshold p­value of 0.05 was considered signifi­
cant. All statistical analyses were performed using the 
Stata 15.0 software.
Trial registration: not relevant.
RESULTS
A total of 22 patients had histologically verified spinal 
malignancy or a positive bone marrow biopsy from the 
iliac crest in the case of multiple myeloma. The remain­
ing eight patients all had MRI­confirmed malignant  
spinal involvement.
PVP was successfully performed on all patients, 
with a total of 81 vertebrae treated. In all, 17 patients 
completed questionnaires at the clinical and radio­
logical follow­up at three months. Sixteen patients an­
swered the mailed questionnaire containing the EQ­5D 
after one year, whereas 17 patients answered the ODI 
questionnaire after one year. The remaining patients 
did not answer any of the questionnaires or died before 
three months post­operatively due to progression of 
their primary cancer. These patients are included in 
data analysis on safety only. 
FIGURE 1
A. Perioperative X-rays 
displaying a trans-
pedicular approach.  
B. Asymptomatic spinal 
leakage (arrow) from 
L1, three months post-
operatively in a 
78-year-old woman 
with chronic lympho-
cytic leukaemia.
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Quality of life
The EQ­5D showed an improvement from 0.32 to 0.62 
(p = 0.005) three months after PVP. This improvement 
was sustained up to one year post­operatively com­
pared with baseline with an increase from 0.36 to 0.61 
(p = 0.011) (Table 2).
Mobility
ODI at baseline was 44.1 with a statistically significant 
improvement to 23.3 (p = 0.003) at the one­year fol­
low­up (Table 2).
Pain
Item 1 of the ODI questionnaire regarding pain (Table 
3) showed a reduction in median pain from 3 to 2, but 
no statistical difference between baseline and the one­
year follow­up (p = 0.753).
Safety
Cement leakage occurred in 12 vertebrae in seven pa­
tients, resulting in a leakage rate of 14.8% when cal­
culated per treated vertebra. The leakages were all 
asymptomatic. No major complications such as spinal 
cord injury, symptomatic pulmonary embolism or 
bleeding were observed.
Posterior wall defects were found in 24 of 81 
treated vertebrae in 13 patients. One of these defects 
resulted in cement leakage to the spinal canal, but the 
patient presented with no neurological symptoms 
(Figure 1B).
DISCUSSION
In this case series counting 30 patients, statistically sig­
nificant improvement in both EQ­5D and ODI scores 
were seen for spinal metastasis treated with PVP at a 
single institution. 
The improvement of the EQ­5D score was 0.30 at 
three months and 0.25 at 12 months after surgery. Both 
these score improvements are more than twice the 
change in EQ­5D scores that is considered the mini­
mum clinically important difference of 0.12 [12]. The 
improvement in ODI from 44.1 to 23.3 can be inter­
preted as change from severe disability to moderate 
disability [13]. This decrease of 20.8 index points is 
greater than the reported minimum clinically impor­
tant difference and also greater than the threshold for 
substantial clinical difference [12]. These improve­
ments in EQ­5D and ODI are similar to previous reports 
[14].
We evaluated pain using item 1 of the ODI question­
naire, which is less nuanced than VAS, since data on 
VAS were not collected prospectively. The inability to 
present a statistically significant reduction in pain 
might be due to the ordinal nature of the item, with 
only six possible answers, and to the small sample size. 
In addition, this makes it difficult to compare the pain 
reduction to reductions reported in previously pub­
lished studies [14].
In this series, the cement leakage rate was 14.8%, 
which is considerably lower than the rates seen in the 
majority of previously published studies [14]. Data on 
injected cement volume was not consistently reported 
by the operators. If the volume used at our institution is 
lower than the volume used in previous studies, this 
might explain the observed difference. Furthermore, 
the actual rate of cement leakage might be higher if im­
aged using CT, but this is not standard procedure at our 
TABLE 1
Patient demographics.
Patients, total, n 30
Age, mean (range), yrs 69.1 (48-86) 
Male, n (%) 20 (66.7)
Primary malignancy, n (%)
Multiple myeloma 13 (43.3)
Lung   6 (20.0)
Chronic lymphocytic leukaemia   5 (16.7)
Lymphoma   2 (6.7)
Gastric   1 (3.3)
Prostate   1 (3.3)
Colon   1 (3.3)
Ovary   1 (3.3)
Treated levels, n (%)
Single   6 (20)
Multiple 24 (80)
Treated spine region, n (%)
Thoracic 37 (45.7)
Lumbar 44 (54.3)
Total 81 (100)
Posterior wall defects, n/N (%) 24/81 (29.6)
Cement leakage, n/N (%) 12/81 (14.8)
Symptomatic complications 0
Survival, n/N (%)
3 mo.s 23/30 (76.7)
1 yr 18/30 (60)
TABLE 2
Quality of life and mobility outcomes.
Post-operatively, mean ± SD (p-value)
Preoperatively, mean ± SD (n) 3 mo.s 1 yr 
EQ-5Da 0.32 ± 0.36 (15) 0.62 ± 0.22 (0.005) –
0.36 ± 0.38 (14) – 0.61 ± 0.35 (0.011)
ODI 44.1 ± 19.2 (17) – 23.3 ± 17.3 (0.003)
EQ-5D = European Quality of Life – 5 Dimensions Questionnaire; ODI = Oswestry Disability Index;  
SD = standard deviation.
a) Of patients who answered the questionnaire at both baseline and the corresponding follow-up.
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institution. Posterior wall defect is, by some clinicians, 
considered a relative contraindication to PVP because 
of the perceived higher risk of neurological complica­
tions [9]. Similar to the study by Sun et al [15], our re­
sults did not indicate any increased risk of complica­
tions when treating vertebrae with posterior wall 
defects.
Our study has some limitations, including missing 
perioperative biopsies from some patients with mul­
tiple myeloma, because the former practice at our in­
stitution relied on the bone marrow biopsy and radio­
logical findings alone. This might have led to an 
overestimation of multiple myeloma patients because 
we cannot rule out osteoporosis as the cause of these 
fractures. This has led to a change in the clinical prac­
tice at our institution. A biopsy is now standard proced­
ure as part of the PVP despite the establishment of a 
preoperative diagnosis. We experienced a considerable 
loss to follow­up due to patient dropout. This is to be 
expected when conducting studies involving patients in 
palliative treatment with a limited life expectancy. This 
might have led to an overestimation of the efficacy 
since the patients in the best general condition and who 
enjoyed the largest effect of the treatment participated 
in the follow­ups. Furthermore, the substantial loss to 
follow­up meant that we had two different EQ­5D base­
line values, when performing the paired t­tests.
The study population included eight patients with 
spinal malignancy verified by radiology alone. This re­
duces the diagnostic accuracy, but a sensitivity of 
98.5% has been reported when detecting osseous  
metastasis of the spine using MRI [16]. 
Finally, our study does not include a control group. 
This makes us unable to comment on any spontaneous 
improvement and healing of the fracture. Spontaneous 
improvements, measured at three months and one 
year, seem highly unlikely in a study population with 
advanced cancer. Spontaneous healing of osteoporotic 
vertebral compression fractures is reported to occur 
within three months [17], but the natural course of ma­
lignant lesions is a speculative area. The survival rates 
in this study indicate that these patients might not live 
long enough to profit from the spontaneous healing of 
the fracture. An exception to this statement is patients 
with multiple myeloma who generally survive longer 
[18].
The only randomised controlled trial on malignant 
vertebral compression fractures indicates that kyph­
oplasty (an advanced form of vertebroplasty using a 
balloon to restore vertebral height) is superior to con­
servative treatment [19]. The retrospective nature of 
our study prevents us from utilising blinding, which 
stops us from quantifying any placebo effect.
In many cases, the patients were referred to our in­
stitution late in their oncological treatment. This might 
lead to a non­malignant biopsy at the time of operation 
and an underestimation of patients with fractures of a 
malignant origin. 
Cancer patients are at an increased risk of having or 
developing osteoporosis because of the relatively ad­
vanced age at the time of diagnosis and the addition of 
oncological treatment such as chemotherapy (inducing 
hypogonadism), hormone ablative therapy, glucocor­
ticoids, surgical castration and irradiation [20]. This 
leads to the hypothesis that vertebral compression frac­
tures might be caused by a combination of infiltrative 
neoplastic changes and reduced bone quality.
CONCLUSIONS
Vertebroplasty is a minimally invasive and safe verte­
bral augmentation therapy for painful vertebral com­
pression fractures in patients with malignant spinal le­
sions, which makes it ideal for palliative treatment. We 
showed a statistically significant and clinically relevant 
increase in quality of life measured by the EQ­5D and 
mobility measured by the ODI. We observed no differ­
ence in the level of pain compared with baseline. To 
control for confounders and the risks of bias, ran­
domised controlled trials should be performed.
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